| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Departments of Pathology,* Neuropathology, Head and Neck Surgery, Biometrics, and Immunology,¶ Otto-von-Guericke University, Magdeburg, Germany
The allele constitution at codon 72 of the p53 gene (CGC-arginine or CCC-proline) plays a major role in inducing apoptosis in p53 mutant cells. To verify this, we determined GC-status, p53-mutations, and p53-loss of heterozygosity (LOH) in a group of 54 squamous cell carcinomas of the head and neck (SCCHN). A novel approach, using a one-step real-time PCR analysis with fluorescent hybridization probes, was applied to detect the GC status in tumors and corresponding blood samples. p53 mutations in exons 4 to 8 were detected by PCR-SSCP-sequencing analysis. Apoptosis was determined immunohistochemically using antibodies against Fas, FasL, p53, Bcl2, and terminal deoxy-transferase-mediated dUTP nick end labeling (TUNEL) staining. The overall frequency of p53-LOH in SCCHN was 45.2%. In cases of LOH, there was a preferential loss of the proline allele, which was associated with an up-regulation of Bcl2 and lack of co-expression of Fas/FasL and, thus, impaired apoptosis (P < 0.001). Apoptosis was not observed in tumors carrying the arginine allele. p53 mutations were detected in 29.6% of SCCHN and preferentially occurred at the arginine allele (P = 0.01). p53 alterations were more frequently observed in tumors of the oral cavity, oropharynx and hypopharynx, whereas they were rare in larynx carcinomas (P = 0.07). The p53-LOH status was not found to be significantly correlated with sex, age, TNM-status, or tumor grading. We conclude that apoptosis is correlated with the allelic status of codon 72 in SCCHN. Homozygous proline 72 appears to be an important regulator of apoptosis via the Fas/FasL pathway in SCCHN.
This article has been cited by other articles:
 |
|
 |
|
  N. A. Ellis, D. Huo, O. Yildiz, L. J. Worrillow, M. Banerjee, M. M. Le Beau, R. A. Larson, J. M. Allan, and K. Onel MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility Blood, August 1, 2008; 112(3): 741 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chen, Z. Hu, L.-E Wang, E. M. Sturgis, A. K. El-Naggar, W. Zhang, and Q. Wei Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck Carcinogenesis, September 1, 2007; 28(9): 2008 - 2012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Mitra, S Banerjee, C Misra, R K Singh, A Roy, A Sengupta, C K Panda, and S Roychoudhury Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population J. Clin. Pathol., September 1, 2007; 60(9): 1040 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-Z. Zhu, A.-Z. Wang, H.-R. Jia, X.-X. Jin, X.-L. He, L.-F. Hou, and G. Zhu Association of the TP53 Codon 72 Polymorphism with Colorectal Cancer in a Chinese Population Jpn. J. Clin. Oncol., May 1, 2007; 37(5): 385 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Nelson, M. Wilkojmen, C. J. Marsit, and K. T. Kelsey TP53 mutation, allelism and survival in non-small cell lung cancer Carcinogenesis, October 1, 2005; 26(10): 1770 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tommiska, H. Eerola, M. Heinonen, L. Salonen, M. Kaare, J. Tallila, A. Ristimaki, K. von Smitten, K. Aittomaki, P. Heikkila, et al. Breast Cancer Patients with p53 Pro72 Homozygous Genotype Have a Poorer Survival Clin. Cancer Res., July 15, 2005; 11(14): 5098 - 5103. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
